Amendment to the European Standard for Risk Management of Medical Devices
An European amendment to EN ISO 14971 - Medical devices - Application of risk management to medical devices, designated A11:2021, was published in December 2021, paving the way to the standard being listed in the Official Journal of the European Union (OJEU) as providing a presumption of conformity with the relevant requirements of the European Medical Device and In Vitro Diagnostics Regulations.
Liliana Teles

Liliana Teles

Regulatory Affairs Manager

The amendment replaces the European foreword and adds two new Annexes – ZA and ZB – stating the relationship between the clauses of the standard and the requirements of the Medical Devices Regulation (MDR (EU) 2017/745) and In Vitro Diagnostics Regulation (IVDR (EU) 2017/746).

The MDR and IVDR present more detailed requirements for the risk management process compared with the previous Directives. On the whole, the harmonization of ISO 14971:2019 as EN ISO 14971:2019+Amd 11:2021 is great news for the Medical Device manufacturer as it shows a stronger relationship between the standard and the risk management process required in the Regulations.

There are no content deviations in the Z Annexes of EN ISO 14971:2019+A11:2021. The Z Annexes state that once the standard has been published in the OJEU, compliance with the standard will give a presumption of conformity with the relevant General Safety and Performance Requirements (GSPRs) of the MDR and IVDR.

Tables in Annex ZA and ZB show the relationship between the GSPRs in Annex I of each regulation with the clauses of EN ISO 14971. In particular, the tables address:

– GSPR 3 regarding the manufacturer’s risk management system;

– GSPR 4 regarding risk control measures;

– GSPR 5 regarding elimination or reduction of risks;

– GSPR 8 regarding known and foreseeable risks, and undesirable side-effects; and,

– GSPR 9 of the MDR regarding devices without a medical purpose.

In applying the standard considering new Annex Zs , it is important to note that:

– The tables indicate that, in regard to some of the requirements of the regulations, the standard covers the process requirements but not the device-specific execution of the process;

– The scope of application is limited to medical devices, accessories for a medical device as defined in the regulations and to products regulated as devices under the regulations;

– Z Annexes contain a number of explanatory notes stating that the manufacturer must comply with certain requirements of the MDR and IVDR which override any content of the standard;

– Annex ZA states that usability-specific aspects of applicable GSPRs are not covered. IEC 62366 covers usability of Medical Devices and it is expected to be harmonised in due course;

– The risk management process must comply with the requirement in the regulations that risks have to be reduced as far as possible and the manufacturer’s policy for establishing criteria for risk acceptability has to comply with the GSPRs of the regulations.

References:

  1. EN ISO 14971:2019+A11:2021, on application of risk management to medical devices

further
reading

drug_device_combination_1
medical devices

Regulatory Framework of Drug-Device Combination

The advances in technology continue to merge different types of products and the historical lines of separation between medical devices and medicinal products are getting thinner. Products combining medicinal products and medical devices are regulated either by Regulation (EU) 2017/745 (MDR) or by Directive 2001/83/EC.

Read More »
cosmetic products

SCCS Preliminary Opinion on Alpha-Arbutin and Beta-Arbutin

Alpha-arbutin and Beta-arbutin are used in cosmetic with antioxidant, bleaching and skin conditioning functions. Following concerns raised during discussion within the Working Group on Cosmetic Products and consequent call for data on these ingredients, the SCCS assessed the safety of Alpha-arbutin and Beta-arbutin in cosmetic products.

Read More »
cosmetic products

Request for SCCS Scientific Opinion on Citral

The European Commission requested the SCCS to assess whether the derived safe use levels for Citral by the application of the QRA2 based on the induction of skin sensitization is adequate to protect consumers. A period of 9 months was set for issuing the scientific opinion.

Read More »
cosmetic products

SCCS Scientific Advice on the Safety of Triclocarban and Triclosan

The European Commission Scientific Committee on Consumer Safety (SCCS) has published its preliminary version of the scientific advice on the safety of Triclocarban and Triclosan as substances with potential endocrine disrupting properties in cosmetic products. The deadline for comments was set at 27 May 2022.

Read More »
cosmetic products

Cosmetic Regulation in the Andean Community

In the Andean Community (Bolivia, Colombia, Ecuador and Peru), cosmetic products are mainly regulated by Decision 833. All cosmetic products made available in these countries must undergo a Mandatory Sanitary Notification (NSO) and need to be manufactured according to Good Manufacturing Practices (GMP).

Read More »
cosmetic products

Cosmetic Product Labelling in the European Union

The Regulation (EC) No 1223/2009 lays down the mandatory information that needs to be included in the packaging and container of a cosmetic products. In addition to this information, most cosmetic products include certain claims, which must be supported and properly substantiated.

Read More »
cosmetic products

Environmental Claims in the UK

Green claims are a trend among consumer goods and services. We often see claims like ‘clean beauty’, ‘environmental friendly’ and so many others. But how can companies ensure that these claims are not misleading? The UK’s Competition and Markets Authority (CMA) has published its Green Claims Code, in order to help companies comply with legal obligations when making environmental claims.

Read More »
cosmetic products

Parabens in Cosmetic Products

Parabens are widely used as preservatives in cosmetic and personal care products. Over the years, there have been some concerns related to the safety of parabens. The SCCS has published several opinions regarding the use of these ingredients in cosmetics, indicating the concentration levels they considered safe for human health. In the EU, some parabens can be safely used as preservatives, while others are prohibited in cosmetic products.

Read More »
cosmetic products

The Product Information File (PIF)

A Product Information File (PIF) is mandatory for all cosmetic products placed in the European Union market. It is a document that compiles the technical information of the cosmetic product and it must be kept for a period of 10 years by the Responsible Person.

Read More »